Introduction
In the 1970s, 70% of all bacteraemias in neutropenic patients were caused by Gram-negative organisms, but in the 1980s viridans streptococci became the major cause of bacteraemia in these patients 1 and in the 1990s these pathogens have become increasingly resistant to penicillin. 2 A recent, large-scale surveillance programme covering the USA, Canada and Latin America has reported that streptococcal isolates are responsible for 9.8% of all bloodstream infections. 3 Whereas Streptococcus pneumoniae was the most frequently isolated pathogen (50.7%), -haemolytic streptococci (32.8%) and viridans streptococci (16.5%) were also commonly observed.
The first quinolones had virtually no activity against Gram-positive bacteria. Gradually, new derivatives, which combined activity against Gram-positive and Gram-negative organisms, were developed. 4 Gemifloxacin is a novel quinolone with a wide spectrum of activity against both Gram-negative and Gram-positive aerobes, including Staphylococcus aureus, penicillinresistant pneumococci and enterococci, and anaerobic organisms. [5] [6] [7] [8] [9] This study investigated the potency of gemifloxacin, ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, penicillin, ampicillin, clarithromycin and azithromycin against 50 recent clinical isolates of Streptococcus pyogenes, Streptococcus agalactiae and viridans streptococci. 
Materials and methods

Antimicrobial agents
Bacterial isolates
Bacterial isolates were cultured from specimens obtained from outpatients and hospital inpatients, and were supplied by the Microbiology Laboratory, University Hospital, Antwerp, Belgium.
This study tested 50 isolates each of S. agalactiae, S. pyogenes and viridans streptococci collected between 1 January 1998 and 19 March 1999. 
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In vitro
MIC determination
Organisms were kept frozen at -20°C until tested. For testing, isolates were subcultured overnight on Columbia agar (Becton-Dickinson, Cockeysville, MD, USA) with 5% horse blood. Bacteria were suspended in Mueller-Hinton broth (Becton-Dickinson) at a density corresponding to that of a 0.5 McFarland standard. MICs were determined in microtitre trays incubated at 37°C in air, using the NCCLS microdilution method. 10 Breakpoints used were those recommended by the NCCLS: grepafloxacin, р0.5 mg/L; trovafloxacin, р1 mg/L; levofloxacin, р2 mg/L; ofloxacin, р2 mg/L (for -haemolytic streptococci); clarithromycin, р0.25 mg/L; azithromycin, р0.5 mg/L; penicillin, р0.12 mg/L and ampicillin, р0.25 mg/L.
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Escherichia coli ATCC 25922 and ATCC 35218, Pseudomonas aeruginosa ATCC 27853, S. aureus ATCC 29213 and Enterococcus faecalis 29212 were included in each run as control organisms. Results were only accepted when the data obtained using these control strains were within the ranges recommended by the NCCLS.
Results
The activity of gemifloxacin against the aerobic Grampositive organisms investigated in this study is shown in the Table. The majority of isolates were highly susceptible to gemifloxacin (MIC 90 р 0.06 mg/L). Gemifloxacin was significantly more active than the other test quinolones against S. pyogenes with the exception of trovafloxacin, where the difference was only a factor of two. However, the MIC 90 of trovafloxacin against S. agalactiae and viridans streptococci was four-fold higher than that of gemifloxacin (0.25 and 0.06 mg/L, respectively).
Four isolates of S. agalactiae showing intermediate 52 Gemifloxacin was as potent against S. agalactiae as penicillin, and six-fold more potent than penicillin against the viridans streptococci tested. Of all the test isolates, only S. pyogenes was considerably more sensitive to penicillin than to gemifloxacin. However, it is known that S. pyogenes is exquisitely sensitive to penicillin (MIC 90 р 0.015 mg/L), and this study also found this organism to be sensitive to gemifloxacin (MIC 90 р 0.03 mg/L).
Discussion
The susceptibility results recorded in this study for quinolones other than those for gemifloxacin against viridans streptococci reflect those published previously.
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Similar activity against -haemolytic streptococci has also been noted in a recent study. 4 Although those investigators recorded a significantly higher MIC (MIC 90 0.25 mg/L) of penicillin for -haemolytic streptococci, it is possible that their sample of -haemolytic streptococci contained species other than S. pyogenes, such as S. agalactiae. The MIC values for viridans streptococci in that study were not significantly different from those found in this study.
The increasing prevalence of penicillin-resistant viridans streptococci was described by Carratala et al. 12 in 1995 and confirmed by other studies. 13, 14 In 1995, Alcaide et al. 15 observed penicillin resistance (MIC 0.25-8 mg/L) in 33.6% of 410 isolates of viridans streptococci. Some crossresistance with other -lactams was also noted. The findings of this study indicate that gemifloxacin has excellent activity against Gram-positive organisms, in addition to its efficacy against Gram-negative organisms and anaerobes. [6] [7] [8] 10 Based on these preliminary observations, gemifloxacin would also appear to be active against streptococci that are resistant to other quinolones. Gemifloxacin appears to be a very promising antimicrobial agent for clinical use in the treatment of streptococcal infection, providing that it can be shown to have a favourable pharmacokinetic profile and low toxicity.
